Pfizer tracks RSV shot safety in over 1,000 seniors
NCT ID NCT06546800
Summary
This study is monitoring the safety of the Abrysvo RSV vaccine in adults aged 60 and older in Japan. It will follow about 1,100 people for 28 days after they receive the vaccine to check for any side effects. The goal is to confirm the vaccine's safety in real-world use after its approval.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer
Tokyo, Japan
Conditions
Explore the condition pages connected to this study.